OKYO Pharma logo

OKYO - OKYO Pharma News Story

14.65p -2.1  -12.5%

Last Trade - 11/08/20

Small Cap
Market Cap £93.9m
Enterprise Value £93.8m
Revenue £n/a
Position in Universe 954th / 1819

OKYO Pharma Limited - Directorate Change

Thu 19th December, 2019 7:00am
RNS Number : 3948X
OKYO Pharma Limited
19 December 2019





OKYO Pharma Limited ("OKYO" or the "Company") is pleased to announces that Gregor MacRae has been appointed as a non-executive director of the company with immediate effect. Leopoldo Zambeletti is simultaneously standing down as a director of the Company with immediate effect.


Gregor is a business adviser, who specialises in taxation and cross border solutions. Presently, Gregor is the Senior Partner of Appledore Wealth Management LLP which is a London-based high net worth business advisory partnership. Previously, Gregor has been a director of an international trust company (Vistra UK Limited, formerly Chiltern Group Plc), which included holding the position of managing director of the taxation and private client groups.


Gregor holds a degree in Law from University of Birmingham (LLB Hons) and is a qualified Chartered Accountant (ICAEW).


Gregor will chair the Audit and Risk Committee of the Board (which also comprises Willy Simon) and will sit as a member of the Remuneration Committee (which also comprises Willy Simon as chairman).


Willy Simon, Chairman of OKYO, said "We are delighted that Gregor has joined the Board of OKYO.  His expertise will be of great value to us.  He is a great addition to the Board at a very important time for the group. I thank Leopoldo for his contribution to the Board and the Company and wish him well in his other interests". 


Gregor is also a director of B C Estate Limited and senior partner of Appledore Wealth Management LLP. Save as disclosed herein, there are no further details required to be disclosed pursuant to Listing Rule 9.6.13 in connection with Gregor's appointment.


About OKYO


OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.





OKYO Pharma Limited

Willy Simon


+44 (0)20 7382 8300

Shore Capital  Limited (Broker)

Antonio Bossi

David Coaten


+44 (0)20 7601 6100

For further information, please visit the Company's website at www.okyopharma.com.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.